RxDoctor Payments DataLook up a doctor →

Floyd Russak, MD

Internal Medicine · Greenwood Village, CONPI 1902898984

Payments from drug & device makers

$17,729in general payments, 2019–2025

Across 747 payments — averaging $23.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4K
  • AbbVie$2K
  • AstraZeneca$2K
  • Novartis$1K
  • Esperion Therapeutics, Inc.$928
  • Novo Nordisk$879
  • plus $7K from 47 others

What the payments were for

  • Food & beverage$17,671100%
  • Education$580%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,729 in reported general payments places this provider in the 95th percentile of 1,430 internal medicine providers in Colorado.

See all internal medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$546,178
Medicare patients
234
Services billed
17,818

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex Pen (4 Pack)Interferon Beta-1a12$96,437
Repatha SureclickEvolocumab129$87,603
MounjaroTirzepatide69$69,529
EliquisApixaban27$38,336
OzempicSemaglutide38$38,292
NexlizetBempedoic Acid/Ezetimibe39$26,604
XareltoRivaroxaban17$21,186
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$13,466
Praluent PenAlirocumab17$11,333
BelsomraSuvorexant18$11,228
JardianceEmpagliflozin14$10,160
Nebivolol Hcl62$4,771
Rosuvastatin Calcium256$4,316
SynthroidLevothyroxine Sodium43$3,375
Estradiol (Twice Weekly)Estradiol26$3,134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$605$69,52969 claims
PfizerEliquis, Paxlovid$146$39,76546 claims
Novo NordiskOzempic$879$38,29238 claims
Esperion Therapeutics, Inc.Nexlizet$928$26,60439 claims
Johnson & JohnsonXarelto$195$21,18617 claims
GSKTrelegy Ellipta$412$13,46611 claims
MerckBelsomra$263$11,22818 claims
Boehringer IngelheimJardiance$124$10,16014 claims
AbbVieSynthroid, Armour Thyroid$2,106$3,95160 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$12$985100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,430 internal medicine providers in Colorado.

Other internal medicine in Greenwood Village

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →